de Jong Margriet F C, Nemeth Elizabeta, Rawee Pien, Bramham Kate, Eisenga Michele F
Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, The Netherlands.
Department of Medicine, University of California, Los Angeles, California, USA.
Kidney Int Rep. 2024 Jan 11;9(5):1183-1197. doi: 10.1016/j.ekir.2024.01.015. eCollection 2024 May.
Chronic kidney disease (CKD), anemia, and iron deficiency are global health issues affecting individuals in both high-income and low-income countries. In pregnancy, both CKD and iron deficiency anemia increase the risk of adverse maternal and neonatal outcomes, including increased maternal morbidity and mortality, stillbirth, perinatal death, preterm birth, and low birthweight. However, it is unknown to which extent iron deficiency anemia contributes to adverse outcomes in CKD pregnancy. Furthermore, little is known regarding the prevalence, pathophysiology, and treatment of iron deficiency and anemia in pregnant women with CKD. Therefore, there are many unanswered questions regarding optimal management with oral or i.v. iron and recombinant human erythropoietin (rhEPO) in these women. In this review, we present a short overview of the (patho)physiology of anemia in healthy pregnancy and in people living with CKD. We present an evaluation of the literature on iron deficiency, anemia, and nutritional deficits in pregnant women with CKD; and we evaluate current knowledge gaps. Finally, we propose research priorities regarding anemia in pregnant women with CKD.
慢性肾脏病(CKD)、贫血和缺铁是影响高收入和低收入国家人群的全球性健康问题。在孕期,CKD和缺铁性贫血都会增加孕产妇和新生儿不良结局的风险,包括孕产妇发病率和死亡率增加、死产、围产期死亡、早产和低出生体重。然而,尚不清楚缺铁性贫血在CKD孕妇不良结局中所起的作用程度。此外,对于CKD孕妇缺铁和贫血的患病率、病理生理学及治疗知之甚少。因此,关于这些女性使用口服或静脉铁剂及重组人促红细胞生成素(rhEPO)的最佳管理,仍有许多问题未得到解答。在本综述中,我们简要概述了健康妊娠和CKD患者贫血的(病理)生理学。我们对有关CKD孕妇缺铁、贫血和营养缺乏的文献进行了评估;并评估了当前的知识空白。最后,我们提出了关于CKD孕妇贫血的研究重点。